| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 73 | 2022 | 561 | 11.960 |
Why?
|
| Carcinoma, Squamous Cell | 52 | 2022 | 629 | 9.580 |
Why?
|
| Mouth Neoplasms | 19 | 2021 | 206 | 4.750 |
Why?
|
| Oropharyngeal Neoplasms | 17 | 2022 | 94 | 3.890 |
Why?
|
| Parotid Neoplasms | 8 | 2020 | 49 | 3.520 |
Why?
|
| Papillomavirus Infections | 10 | 2022 | 194 | 2.720 |
Why?
|
| Free Tissue Flaps | 10 | 2022 | 67 | 2.600 |
Why?
|
| Eyelid Neoplasms | 3 | 2022 | 12 | 2.290 |
Why?
|
| Neck Dissection | 10 | 2022 | 55 | 2.170 |
Why?
|
| Salivary Gland Neoplasms | 4 | 2021 | 40 | 2.020 |
Why?
|
| Papillomaviridae | 6 | 2022 | 104 | 2.010 |
Why?
|
| Lymphatic Metastasis | 13 | 2022 | 274 | 1.980 |
Why?
|
| Thyroid Neoplasms | 5 | 2020 | 68 | 1.680 |
Why?
|
| Humans | 146 | 2022 | 68618 | 1.670 |
Why?
|
| Neoplasm Staging | 18 | 2021 | 800 | 1.650 |
Why?
|
| Precancerous Conditions | 6 | 2020 | 74 | 1.620 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2022 | 16 | 1.540 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2020 | 125 | 1.510 |
Why?
|
| Middle Aged | 79 | 2022 | 21147 | 1.490 |
Why?
|
| Alphapapillomavirus | 3 | 2020 | 17 | 1.470 |
Why?
|
| Aged | 66 | 2022 | 14862 | 1.460 |
Why?
|
| Databases, Factual | 10 | 2020 | 622 | 1.440 |
Why?
|
| Radiation Injuries | 5 | 2015 | 97 | 1.430 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2021 | 14 | 1.420 |
Why?
|
| Xerostomia | 3 | 2015 | 24 | 1.410 |
Why?
|
| Retrospective Studies | 42 | 2022 | 7277 | 1.370 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2022 | 446 | 1.370 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 143 | 1.300 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 154 | 1.290 |
Why?
|
| Male | 87 | 2022 | 37321 | 1.250 |
Why?
|
| Female | 87 | 2022 | 38074 | 1.250 |
Why?
|
| Aged, 80 and over | 28 | 2022 | 4848 | 1.160 |
Why?
|
| Carcinoma | 6 | 2020 | 215 | 1.160 |
Why?
|
| Caregivers | 4 | 2019 | 365 | 1.160 |
Why?
|
| Sirolimus | 3 | 2019 | 118 | 1.150 |
Why?
|
| Survival Rate | 20 | 2021 | 1056 | 1.130 |
Why?
|
| Laryngeal Neoplasms | 6 | 2020 | 47 | 1.110 |
Why?
|
| Prognosis | 24 | 2021 | 2093 | 1.080 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2019 | 118 | 1.020 |
Why?
|
| Laryngectomy | 4 | 2020 | 30 | 0.980 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 23 | 0.960 |
Why?
|
| Betacoronavirus | 3 | 2020 | 116 | 0.960 |
Why?
|
| Salivary Glands | 2 | 2014 | 52 | 0.910 |
Why?
|
| Parotid Gland | 4 | 2016 | 33 | 0.900 |
Why?
|
| Adult | 49 | 2022 | 21403 | 0.900 |
Why?
|
| Cancer Survivors | 3 | 2020 | 146 | 0.850 |
Why?
|
| Survival Analysis | 8 | 2021 | 714 | 0.840 |
Why?
|
| Carcinoma, Papillary | 2 | 2020 | 35 | 0.830 |
Why?
|
| Postoperative Complications | 11 | 2022 | 1615 | 0.830 |
Why?
|
| Quality of Life | 9 | 2020 | 1515 | 0.830 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 18 | 0.820 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 12 | 0.800 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2021 | 4 | 0.760 |
Why?
|
| Tongue Neoplasms | 3 | 2019 | 29 | 0.760 |
Why?
|
| Cutaneous Fistula | 2 | 2020 | 11 | 0.750 |
Why?
|
| Risk Factors | 20 | 2021 | 5731 | 0.750 |
Why?
|
| Pandemics | 3 | 2020 | 352 | 0.720 |
Why?
|
| Registries | 4 | 2017 | 733 | 0.710 |
Why?
|
| Tracheostomy | 1 | 2020 | 31 | 0.710 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 18 | 0.710 |
Why?
|
| Carcinoma in Situ | 1 | 2020 | 47 | 0.700 |
Why?
|
| Patient Readmission | 3 | 2018 | 267 | 0.700 |
Why?
|
| Time-to-Treatment | 3 | 2020 | 117 | 0.690 |
Why?
|
| Body Image | 5 | 2020 | 100 | 0.680 |
Why?
|
| Medical Oncology | 3 | 2020 | 110 | 0.680 |
Why?
|
| Combined Modality Therapy | 18 | 2021 | 951 | 0.660 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2017 | 62 | 0.660 |
Why?
|
| United States | 16 | 2021 | 7367 | 0.660 |
Why?
|
| Survivorship | 1 | 2019 | 20 | 0.640 |
Why?
|
| Students, Dental | 4 | 2007 | 49 | 0.640 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 375 | 0.640 |
Why?
|
| Treatment Outcome | 22 | 2021 | 7029 | 0.620 |
Why?
|
| Laryngitis | 1 | 2018 | 12 | 0.620 |
Why?
|
| Guideline Adherence | 2 | 2018 | 287 | 0.620 |
Why?
|
| Interpersonal Relations | 2 | 2017 | 209 | 0.610 |
Why?
|
| Vocal Cords | 1 | 2018 | 18 | 0.610 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 149 | 0.600 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 81 | 0.590 |
Why?
|
| Needs Assessment | 1 | 2019 | 186 | 0.590 |
Why?
|
| Mesenchymoma | 1 | 2017 | 4 | 0.580 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1046 | 0.570 |
Why?
|
| Maxillary Neoplasms | 2 | 2015 | 12 | 0.570 |
Why?
|
| Lymph Nodes | 1 | 2018 | 258 | 0.560 |
Why?
|
| Myoepithelioma | 1 | 2016 | 2 | 0.550 |
Why?
|
| Early Goal-Directed Therapy | 1 | 2016 | 6 | 0.540 |
Why?
|
| Diagnosis, Differential | 7 | 2018 | 1140 | 0.530 |
Why?
|
| Clinical Competence | 4 | 2010 | 657 | 0.520 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 22 | 0.520 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2006 | 23 | 0.510 |
Why?
|
| Neuroectodermal Tumor, Melanotic | 1 | 2015 | 4 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.510 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2015 | 11 | 0.500 |
Why?
|
| Thyroidectomy | 3 | 2012 | 31 | 0.490 |
Why?
|
| Radiotherapy, Conformal | 2 | 2014 | 24 | 0.490 |
Why?
|
| Specialties, Surgical | 1 | 2014 | 19 | 0.490 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 792 | 0.480 |
Why?
|
| Health Care Reform | 1 | 2014 | 62 | 0.480 |
Why?
|
| Smoking | 4 | 2018 | 1452 | 0.470 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 767 | 0.460 |
Why?
|
| Antibodies, Viral | 2 | 2014 | 110 | 0.460 |
Why?
|
| Mucins | 3 | 2022 | 22 | 0.460 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 475 | 0.450 |
Why?
|
| Melanoma | 3 | 2008 | 335 | 0.440 |
Why?
|
| Prospective Studies | 9 | 2021 | 3705 | 0.420 |
Why?
|
| Neck | 5 | 2022 | 62 | 0.420 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 261 | 0.420 |
Why?
|
| Societies, Medical | 1 | 2014 | 403 | 0.410 |
Why?
|
| Cohort Studies | 9 | 2021 | 2358 | 0.400 |
Why?
|
| Iodine Radioisotopes | 1 | 2012 | 119 | 0.400 |
Why?
|
| Thyroxine | 1 | 2012 | 62 | 0.400 |
Why?
|
| Mandible | 1 | 2012 | 53 | 0.390 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 114 | 0.390 |
Why?
|
| Young Adult | 12 | 2022 | 5717 | 0.390 |
Why?
|
| Biocompatible Materials | 3 | 2012 | 247 | 0.380 |
Why?
|
| Pharyngeal Diseases | 2 | 2021 | 21 | 0.370 |
Why?
|
| Deglutition Disorders | 5 | 2018 | 297 | 0.360 |
Why?
|
| Dentists | 1 | 2010 | 18 | 0.360 |
Why?
|
| Surgical Flaps | 3 | 2018 | 120 | 0.350 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 1174 | 0.350 |
Why?
|
| Body Dysmorphic Disorders | 2 | 2020 | 13 | 0.340 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 349 | 0.340 |
Why?
|
| Ranula | 1 | 2009 | 2 | 0.340 |
Why?
|
| Antineoplastic Agents | 4 | 2012 | 1070 | 0.330 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 425 | 0.330 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 3259 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 536 | 0.320 |
Why?
|
| Adolescent | 11 | 2022 | 8912 | 0.320 |
Why?
|
| South Carolina | 9 | 2019 | 2752 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 129 | 0.310 |
Why?
|
| Ceramides | 6 | 2011 | 578 | 0.290 |
Why?
|
| Scapula | 2 | 2021 | 36 | 0.290 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 35 | 0.290 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 111 | 0.280 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 73 | 0.280 |
Why?
|
| Gastrostomy | 3 | 2018 | 110 | 0.280 |
Why?
|
| Physicians | 1 | 2010 | 324 | 0.270 |
Why?
|
| Mouth Diseases | 1 | 2006 | 39 | 0.270 |
Why?
|
| Hemangiopericytoma | 1 | 2006 | 5 | 0.270 |
Why?
|
| Medicaid | 2 | 2020 | 302 | 0.270 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 132 | 0.270 |
Why?
|
| Temporal Muscle | 1 | 2006 | 2 | 0.270 |
Why?
|
| Fascia | 1 | 2006 | 17 | 0.270 |
Why?
|
| Tobacco Use | 2 | 2018 | 98 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 235 | 0.270 |
Why?
|
| Polyethylenes | 1 | 2006 | 31 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 2324 | 0.260 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2016 | 76 | 0.260 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.260 |
Why?
|
| Hemangioma | 1 | 2006 | 51 | 0.260 |
Why?
|
| Prostheses and Implants | 1 | 2006 | 159 | 0.240 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 160 | 0.240 |
Why?
|
| Sarcoma | 1 | 2005 | 70 | 0.240 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2021 | 33 | 0.230 |
Why?
|
| Depression | 3 | 2019 | 943 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2018 | 2007 | 0.220 |
Why?
|
| Goiter, Nodular | 1 | 2003 | 2 | 0.220 |
Why?
|
| Thyrotoxicosis | 1 | 2003 | 4 | 0.220 |
Why?
|
| Trismus | 1 | 2022 | 3 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 124 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2011 | 468 | 0.210 |
Why?
|
| Attitude to Health | 1 | 2006 | 403 | 0.210 |
Why?
|
| Deglutition | 5 | 2019 | 221 | 0.210 |
Why?
|
| Automobile Driving | 3 | 2008 | 88 | 0.210 |
Why?
|
| Students, Medical | 1 | 2005 | 210 | 0.210 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 442 | 0.210 |
Why?
|
| Endoscopy | 1 | 2006 | 464 | 0.210 |
Why?
|
| Sweat Glands | 1 | 2022 | 10 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 104 | 0.210 |
Why?
|
| Comorbidity | 2 | 2017 | 1426 | 0.200 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 13 | 0.200 |
Why?
|
| Length of Stay | 4 | 2021 | 780 | 0.200 |
Why?
|
| Education, Dental | 3 | 2007 | 63 | 0.200 |
Why?
|
| Smoking Cessation | 3 | 2010 | 1034 | 0.200 |
Why?
|
| Mohs Surgery | 1 | 2021 | 16 | 0.190 |
Why?
|
| Signal Transduction | 5 | 2019 | 2689 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
| Exercise Therapy | 1 | 2022 | 183 | 0.190 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 39 | 0.190 |
Why?
|
| Patient Satisfaction | 3 | 2020 | 378 | 0.180 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 8 | 0.180 |
Why?
|
| Foundations | 1 | 2020 | 17 | 0.180 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 2800 | 0.180 |
Why?
|
| Mouth | 2 | 2019 | 64 | 0.180 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 955 | 0.180 |
Why?
|
| Salvage Therapy | 2 | 2018 | 82 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 30 | 0.170 |
Why?
|
| Child | 6 | 2017 | 6405 | 0.170 |
Why?
|
| Diet | 4 | 2019 | 514 | 0.170 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2019 | 17 | 0.170 |
Why?
|
| Sex Factors | 2 | 2018 | 1266 | 0.170 |
Why?
|
| Clinical Protocols | 1 | 2020 | 172 | 0.170 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 59 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 304 | 0.170 |
Why?
|
| Calcitriol | 2 | 2010 | 106 | 0.160 |
Why?
|
| Immune Evasion | 1 | 2019 | 19 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2019 | 37 | 0.160 |
Why?
|
| Counseling | 4 | 2020 | 280 | 0.160 |
Why?
|
| Logistic Models | 2 | 2017 | 1420 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 18 | 0.160 |
Why?
|
| Cross-Sectional Studies | 7 | 2015 | 2279 | 0.160 |
Why?
|
| Psychology | 1 | 2018 | 36 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 38 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 369 | 0.160 |
Why?
|
| Osteoradionecrosis | 1 | 2018 | 7 | 0.160 |
Why?
|
| Travel | 1 | 2018 | 38 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 756 | 0.150 |
Why?
|
| Age Factors | 3 | 2015 | 1864 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2018 | 331 | 0.150 |
Why?
|
| Life Style | 3 | 2005 | 338 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2019 | 215 | 0.150 |
Why?
|
| Esophageal Stenosis | 2 | 2008 | 36 | 0.150 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 1851 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2018 | 322 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 87 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 14 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2018 | 199 | 0.150 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.150 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 848 | 0.140 |
Why?
|
| Cheek | 1 | 2016 | 11 | 0.140 |
Why?
|
| Exercise | 1 | 2022 | 658 | 0.140 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2008 | 10 | 0.140 |
Why?
|
| Emotions | 1 | 2018 | 244 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 91 | 0.140 |
Why?
|
| Biopsy | 2 | 2017 | 540 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 219 | 0.140 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2016 | 10 | 0.140 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 125 | 0.130 |
Why?
|
| Educational Status | 1 | 2017 | 273 | 0.130 |
Why?
|
| Phosphorylation | 1 | 2018 | 1200 | 0.130 |
Why?
|
| Laryngoscopy | 1 | 2016 | 61 | 0.130 |
Why?
|
| Medically Uninsured | 1 | 2016 | 99 | 0.130 |
Why?
|
| Insurance, Health | 1 | 2017 | 201 | 0.130 |
Why?
|
| Self Disclosure | 1 | 2015 | 55 | 0.130 |
Why?
|
| Telemedicine | 2 | 2020 | 700 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.120 |
Why?
|
| Incidence | 3 | 2015 | 1603 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2015 | 228 | 0.120 |
Why?
|
| Medicare | 1 | 2017 | 319 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1851 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 204 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.120 |
Why?
|
| Social Support | 1 | 2017 | 423 | 0.120 |
Why?
|
| Physician's Role | 1 | 2014 | 116 | 0.120 |
Why?
|
| SEER Program | 1 | 2014 | 153 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 36 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 737 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 344 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2011 | 83 | 0.110 |
Why?
|
| Diagnosis, Oral | 2 | 2010 | 14 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1641 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2016 | 705 | 0.110 |
Why?
|
| Everolimus | 1 | 2012 | 26 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 373 | 0.100 |
Why?
|
| Ilium | 1 | 2012 | 16 | 0.100 |
Why?
|
| Fibula | 1 | 2012 | 13 | 0.100 |
Why?
|
| Bone Transplantation | 1 | 2012 | 43 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2011 | 33 | 0.100 |
Why?
|
| Infant | 2 | 2015 | 2891 | 0.100 |
Why?
|
| Weight Loss | 1 | 2014 | 319 | 0.100 |
Why?
|
| Dental Implants | 1 | 2012 | 39 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2006 | 617 | 0.100 |
Why?
|
| Alcohol Drinking | 3 | 2008 | 805 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2020 | 1342 | 0.090 |
Why?
|
| Electrosurgery | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 26 | 0.090 |
Why?
|
| Microsurgery | 2 | 2018 | 46 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2018 | 867 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 2010 | 25 | 0.090 |
Why?
|
| Oropharynx | 1 | 2010 | 20 | 0.090 |
Why?
|
| Respiratory Aspiration | 1 | 2010 | 13 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 63 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 231 | 0.090 |
Why?
|
| Recurrence | 2 | 2011 | 948 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2006 | 42 | 0.090 |
Why?
|
| Dysphonia | 1 | 2009 | 6 | 0.090 |
Why?
|
| Durapatite | 1 | 2009 | 33 | 0.080 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 18 | 0.080 |
Why?
|
| Mice | 3 | 2018 | 8474 | 0.080 |
Why?
|
| Skull Base | 1 | 2010 | 72 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 454 | 0.080 |
Why?
|
| Animals | 6 | 2019 | 20881 | 0.080 |
Why?
|
| Reoperation | 2 | 2009 | 467 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2009 | 397 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 2223 | 0.080 |
Why?
|
| Tobacco Use Cessation | 2 | 2007 | 44 | 0.080 |
Why?
|
| Pyridinium Compounds | 2 | 2006 | 40 | 0.080 |
Why?
|
| Vitamins | 1 | 2009 | 134 | 0.080 |
Why?
|
| Cranial Nerve Diseases | 1 | 2008 | 14 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2009 | 1174 | 0.080 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2007 | 7 | 0.080 |
Why?
|
| Smoking Prevention | 2 | 2007 | 259 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 383 | 0.070 |
Why?
|
| Telomerase | 2 | 2005 | 85 | 0.070 |
Why?
|
| Temporal Lobe | 1 | 2008 | 125 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 141 | 0.070 |
Why?
|
| Stem Cells | 1 | 2009 | 248 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2009 | 201 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2007 | 71 | 0.070 |
Why?
|
| Mitomycin | 1 | 2007 | 27 | 0.070 |
Why?
|
| Cell Division | 2 | 2005 | 541 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2006 | 312 | 0.070 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2007 | 67 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 24 | 0.070 |
Why?
|
| Mucin-1 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Abdominal Wall | 1 | 2006 | 20 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 82 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2007 | 144 | 0.070 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2006 | 8 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2006 | 48 | 0.070 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2006 | 3 | 0.070 |
Why?
|
| Dentist-Patient Relations | 1 | 2006 | 8 | 0.070 |
Why?
|
| Head | 1 | 2006 | 59 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2007 | 1553 | 0.070 |
Why?
|
| Skull Base Neoplasms | 1 | 2006 | 13 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 124 | 0.070 |
Why?
|
| Rhabdomyosarcoma | 1 | 2006 | 36 | 0.070 |
Why?
|
| Teaching | 1 | 2007 | 169 | 0.070 |
Why?
|
| Periodicity | 1 | 2005 | 43 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 384 | 0.070 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.060 |
Why?
|
| Temporal Bone | 1 | 2006 | 53 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 110 | 0.060 |
Why?
|
| Cotinine | 2 | 2015 | 40 | 0.060 |
Why?
|
| Education, Dental, Continuing | 1 | 2005 | 3 | 0.060 |
Why?
|
| Self Concept | 1 | 2006 | 132 | 0.060 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2005 | 12 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 597 | 0.060 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2005 | 13 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 52 | 0.060 |
Why?
|
| Bone Screws | 1 | 2006 | 90 | 0.060 |
Why?
|
| Mucous Membrane | 1 | 2005 | 66 | 0.060 |
Why?
|
| Communication | 1 | 2007 | 329 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 954 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 150 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 53 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 61 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2005 | 133 | 0.060 |
Why?
|
| Cell Movement | 1 | 2007 | 630 | 0.060 |
Why?
|
| Cognition | 1 | 2008 | 513 | 0.060 |
Why?
|
| Earache | 1 | 2003 | 2 | 0.060 |
Why?
|
| Health Personnel | 1 | 2007 | 286 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 508 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 546 | 0.060 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 123 | 0.060 |
Why?
|
| Oral Surgical Procedures | 1 | 2003 | 15 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2005 | 148 | 0.050 |
Why?
|
| Enteral Nutrition | 2 | 2018 | 157 | 0.050 |
Why?
|
| Curriculum | 1 | 2007 | 575 | 0.050 |
Why?
|
| Carcinoma, Verrucous | 1 | 2002 | 5 | 0.050 |
Why?
|
| Erythroplasia | 1 | 2002 | 6 | 0.050 |
Why?
|
| Leukoplakia, Oral | 1 | 2002 | 12 | 0.050 |
Why?
|
| Health Education | 1 | 2005 | 279 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2018 | 880 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1465 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 581 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 15 | 0.050 |
Why?
|
| Tobacco | 1 | 2002 | 161 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 66 | 0.050 |
Why?
|
| Pharyngectomy | 1 | 2020 | 3 | 0.050 |
Why?
|
| Proteins | 1 | 2004 | 474 | 0.050 |
Why?
|
| Nomograms | 1 | 2020 | 19 | 0.050 |
Why?
|
| Patient Advocacy | 1 | 2020 | 40 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2020 | 49 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 85 | 0.040 |
Why?
|
| Feeding Methods | 1 | 2019 | 17 | 0.040 |
Why?
|
| Composite Tissue Allografts | 1 | 2019 | 8 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 201 | 0.040 |
Why?
|
| Glossectomy | 1 | 2019 | 9 | 0.040 |
Why?
|
| Cell Count | 2 | 2010 | 248 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 99 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 59 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 35 | 0.040 |
Why?
|
| Social Isolation | 1 | 2019 | 40 | 0.040 |
Why?
|
| Microcirculation | 2 | 2009 | 77 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 242 | 0.040 |
Why?
|
| Cisplatin | 2 | 2010 | 192 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 371 | 0.040 |
Why?
|
| Fistula | 1 | 2018 | 29 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 106 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1753 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2019 | 111 | 0.040 |
Why?
|
| Reference Values | 2 | 2010 | 579 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 45 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2017 | 60 | 0.040 |
Why?
|
| Psychometrics | 1 | 2020 | 514 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.040 |
Why?
|
| Health Promotion | 1 | 2021 | 407 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 447 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Chromatography, Liquid | 2 | 2007 | 120 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 468 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 53 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 504 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 786 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 63 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Larynx | 2 | 2007 | 49 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2006 | 223 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 130 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 284 | 0.030 |
Why?
|
| Pharynx | 2 | 2007 | 89 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 136 | 0.030 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1994 | 29 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2014 | 24 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 100 | 0.030 |
Why?
|
| Tolonium Chloride | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 20 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2014 | 144 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 139 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 191 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 320 | 0.030 |
Why?
|
| Physical Examination | 1 | 2014 | 152 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 1994 | 267 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2011 | 5 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2017 | 659 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2010 | 35 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 27 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 39 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 249 | 0.020 |
Why?
|
| Mast Cells | 1 | 2010 | 113 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2010 | 66 | 0.020 |
Why?
|
| Ointments | 1 | 2009 | 15 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 245 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 140 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 442 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 230 | 0.020 |
Why?
|
| Injections | 1 | 2009 | 119 | 0.020 |
Why?
|
| Perforin | 1 | 2009 | 12 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 59 | 0.020 |
Why?
|
| Granzymes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Video Recording | 1 | 2010 | 145 | 0.020 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Tonsillar Neoplasms | 1 | 2008 | 7 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2010 | 152 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 75 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 567 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 226 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2008 | 93 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 114 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 59 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2008 | 132 | 0.020 |
Why?
|
| Mediastinum | 1 | 2008 | 39 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2009 | 110 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2008 | 47 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 115 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 266 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 241 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 219 | 0.020 |
Why?
|
| Papillomavirus Vaccines | 1 | 2008 | 93 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3187 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 447 | 0.020 |
Why?
|
| Reaction Time | 1 | 2007 | 170 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 371 | 0.020 |
Why?
|
| Rectus Abdominis | 1 | 2006 | 9 | 0.020 |
Why?
|
| Models, Educational | 1 | 2007 | 67 | 0.020 |
Why?
|
| Dilatation | 1 | 2007 | 58 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 109 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 13 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2006 | 28 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2006 | 41 | 0.020 |
Why?
|
| Movement | 1 | 2007 | 179 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2006 | 254 | 0.020 |
Why?
|
| Cations | 1 | 2006 | 51 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 306 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 16 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 78 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 22 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2007 | 72 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 183 | 0.020 |
Why?
|
| Cobalt | 1 | 2006 | 37 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2006 | 37 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2007 | 209 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 230 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 213 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 71 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 1593 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 282 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2006 | 108 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2083 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 319 | 0.020 |
Why?
|
| Ligands | 1 | 2006 | 317 | 0.020 |
Why?
|
| Attention | 1 | 2007 | 225 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 238 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2008 | 419 | 0.020 |
Why?
|
| Sphingosine | 1 | 2007 | 315 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 507 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2005 | 17 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 226 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2007 | 254 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 250 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 2005 | 31 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2005 | 51 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 532 | 0.020 |
Why?
|
| Trypan Blue | 1 | 2004 | 24 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 166 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2004 | 36 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1034 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2004 | 66 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2007 | 342 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 200 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 251 | 0.010 |
Why?
|
| Thiazoles | 1 | 2004 | 95 | 0.010 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2004 | 62 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 706 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 331 | 0.010 |
Why?
|
| Ear | 1 | 2003 | 12 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1038 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2673 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 852 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 710 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 981 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 1619 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 1330 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1664 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 643 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1994 | 47 | 0.010 |
Why?
|